Compare Medpace Holdings Inc (MEDP) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Upstart Holdings Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Upstart Holdings Inc trades at $24.1 (market cap $2.35B). The key difference: Medpace Holdings Inc is far larger — about 7.2× Upstart Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Upstart Holdings Inc for 39 Days on average.
| MEDP | UPST | |
|---|---|---|
Market Cap | $16.82B | $2.35B |
Volume | 223,093 | 4,203,337 |
Sector | Health | Financials |
52-Week High | $630.19 | $52.74 |
52-Week Low | $393.42 | $22.81 |
Typical Hold Time | 14 Days | 39 Days |
Enterprise Value | $16.44B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
UPST trades at $24.19, up 0.71% with bearish technical signals despite recent partnership expansions. The company shows improving fundamentals with revenue growing to $1.02B in 2025 and achieving profitability with $53.6M net income. However, recent earnings misses and negative operating cash flow of -$147.73M raise concerns. Analyst sentiment remains divided with a $39.50 price target suggesting 63% upside potential from current levels.
The stock presents a high-risk opportunity with significant upside potential if the company can sustain revenue growth and improve cash flow generation. Key risks include ongoing earnings volatility, credit market sensitivity, and high debt levels. The AI lending platform's expansion into HELOC and auto lending could drive future growth, but execution remains critical for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
